Key Takeaways
- Steady quarter, transformation bets placed: Urea ran at optimal capacity while the CPC & SN segment delivered 26% YoY revenue growth with margin expansion. The real story is the capital being deployed into TAN, phosphates, seeds and biologicals.
- TAN project is locked in: Statutory approvals secured, equipment arriving, civil work done, and cumulative spend at ₹541 cr. Management is confident of commercial production by January 2026, with trials starting earlier.
- Phosphate ambitions go global: The IMACID expansion to 7 lakh MT and active negotiations to secure phosphate supply chains in resource-rich countries signal a deliberate push to become a global phosphate player, not just an Indian one.
- Crop protection and seeds are the next growth engine: The segment is adding 3-4 new products every year, entering seeds with hybrid wheat and mustard from Kharif '25, and building a biologicals pipeline with TERI.
- What to watch next quarter: The TAN project's construction milestones and trial-readiness, any announcement on phosphate supply chain deals, and the ramp-up of new CPC product launches in Kharif 2025.
TAN Project: The Next Big Bet
- Timeline is firming up: Statutory approvals are in place, equipment deliveries have started, and civil and construction works are completed. Cumulative spend reached ₹541 cr (₹466 cr as of Dec 31 plus ₹75 cr in January 2025).
- Commercial production by January 2026: Management confirmed this is the date for commercial production delivery, meaning the plant meets all parameters. Trials will begin before that date.
- Delay was strategic, not a setback: The project was pushed back to accommodate LDAN equipment alongside the original configuration, avoiding a future long shutdown of 4-10 months to retrofit it later.
- FY27 contribution assured: Management stated the plant will "definitely have positive contribution in FY27" and will ramp up "very soon," though they are not being too aggressive on estimates.
- Breakeven is comfortable: While management declined to disclose the exact breakeven utilization, they stated the plant would be above breakeven even at 80-85% utilization.
- Oversupply risk acknowledged but contained: Management conceded there could be oversupply in the next 2-3 years as other capacities come online, but argued it will not last long and that Chambal's cost structure gives it an edge.
Baijal: "Assuming that they do come, it is not going to be very long in the sense that there is not too much of overcapacity. So, I think it will also depend on what is the cost structure of the other person that's where Chambal does score."
Phosphate Strategy: Going Global
- IMACID expansion approved: The board approved expanding phosphoric acid capacity from ~5 lakh metric tons to 7 lakh metric tons, with a total investment of ~$173 million and completion by FY27-28. The sulphuric acid plant study for narrowing down cost is still ongoing.
- Supply chain security is the priority: Chambal is actively in discussions to secure phosphate supply chains in phosphate-rich countries, with active interest on both sides. Management described this as a potential breakthrough that would create "a very strong base for Chambal to be a global phosphate player."
- International investments ahead: These phosphate moves will lead to international investments, and the ambition is a global business, not just one serving India. No government role is expected.
- Marketing handled by OCP: OCP remains the lead in marketing for IMACID. Long-term supply agreements with India continue, and excess production can go to world supply.
- Chambal's share requires no fresh equity: IMACID has enough cash to fund the expansion, so Chambal does not have to invest additional capital.
Baijal: "I think that will be one of the breakthroughs that if I could do, or the Company could do during this time, that will create a very strong base for Chambal to be a global phosphate player."
CPC & SN Segment: The Growth Engine
- Strong top-line momentum: Revenue grew 26% YoY in Q3 and 19% in the nine-month period. Contribution grew even faster at 39% in Q3 and 38% in 9M, indicating margin expansion.
- Product pipeline is deliberate: Growth is driven by introducing Generation 1X molecules, creating alliances with research-based companies, and launching 3-4 new products every year. The company expects to continue growing at current rates or better.
- New launches in the pipeline: Two new weedicides were introduced in Q3. A range of new products, including Generation 1X chemistry in collaboration with partners, will be introduced in Kharif and Rabi 2025.
- Revenue target clarification: The FY27 target of ₹1,750 crore was stated on a gross basis, while segment results are reported on a net basis after trade discounts. The net number is roughly 20-22% lower than the gross number.
- Volume vs price split undisclosed: Management declined to break out volume growth versus price growth for the segment's 19% nine-month and 26% Q3 revenue growth on the call, directing the analyst to discuss it offline.
Seeds & Biologicals: Planting for the Future
- Seeds entry is imminent: The company expects to start sales and marketing of hybrid wheat, mustard, millet, and maize from Kharif 2025 onwards. Partnerships for these crops are already tied up.
- Biologicals gaining traction: A biological fungicide and nematicide will be shortly introduced after successful internal field tests. The company has a systematic program running with TERI, with targeted products in the pipeline.
- CFCL-TERI Centre of Excellence: An agreement with TERI is in place for research on advanced and sustainable agriculture solutions. IP rights are jointly owned, and Chambal has exclusive global commercial rights for products developed over the next five years. Labs and equipment are mostly in position, and work starts from March onwards.
- Capital allocation post-TAN: Once the TAN project is complete, capital will flow into four areas: global phosphate supply chain, seeds (possibly with inorganic moves), biologicals (targeting ₹300-400 crore in sales), and specialty nutrients.
Urea & Core Operations
- Production steady, sales up: All urea units operated at optimal capacity. Production was nearly flat YoY at 9.18 lakh tons versus 9.19 lakh tons, while sales grew from 8.92 to 9.88 lakh tons.
- Subsidy receipts remain timely: ₹3,350 crore was received in Q3, continuing the pattern of smooth subsidy flows.
- Energy efficiency improving: Energy efficiency increased by 3%, with a rough computation of 3% saving from ₹5,000 per Gcal. These gains add to EBITDA but are subject to a gain-sharing formula with the government.
- Q4 volume to dip on planned shutdown: Urea volume is estimated to be 1 lakh to 1.5 lakh tons below the normal run rate due to a ~30-day annual turnaround at Gadepan-III plus minor shutdowns at Gadepan-I and II.
- DAP is a placeholder, not a profit centre: The company did roughly 1 lakh tons of DAP sales in Q3 primarily to keep the channel lubricated. Management confirmed DAP is "a zero-sum game at the moment."
Baijal: "DAP is a zero-sum game at the moment. And we haven't done too much of DAP."
Energy & Cost Strategy
- Preparing for a decontrolled world: Management is deliberately driving energy efficiency improvements to ensure Chambal has "one of the finest cost structures all over the world" if urea ever gets decontrolled.
- Continuous improvement cycle: Energy efficiency projects happen every 2-2.5 years based on studies, with 3-4 other projects already planned. The 3% improvement this quarter is part of an ongoing process.
- Incremental production also adds value: Beyond energy efficiency, the 125 metric tons per day of incremental production adds to EBITDA, though additional production beyond the Reassessed Annual Capacity gets compensation based on import prices of urea and the dollar.
Baijal: "Because we want to be prepared for a day when this may get decontrolled and we should be, in terms of cost structure, one of the finest cost structures all over the world."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| TAN commercial production | Plant meets all parameters and delivers commercial production | January 2026 |
| TAN trials begin | Trials start before commercial production date | Before January 2026 |
| TAN positive contribution | Plant contributes positively to financials | FY27 |
| IMACID expansion production | Phosphoric acid plant goes into production | End of CY26 or early CY27 |
| IMACID expansion completion | Full expansion to 7 lakh MT complete | FY27-28 |
| Seeds sales launch | Hybrid wheat, mustard, millet, maize sales begin | Kharif 2025 onwards |
| New CPC products launch | Generation 1X and other new products introduced | Kharif and Rabi 2025 |
| CFCL-TERI Centre work begins | Research work commences | March 2025 onwards |
| Biological fungicide/nematicide launch | Product introduced to market | Shortly (no fixed date) |
| Q4 urea volume | 1-1.5 lakh tons below normal run rate | Q4 FY25 |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Standalone EBITDA | ₹843 cr, +16% YoY |
| Standalone PAT | ₹505 cr, +25% YoY |
| Consolidated PAT | ₹534 cr, +16% YoY |
| 9M standalone EBITDA | ₹2,619 cr, +19% YoY |
| 9M standalone PAT | ₹1,557 cr, +25% YoY |
| 9M consolidated PAT | ₹1,519 cr, +29% YoY |
| Urea production | 9.18 lakh metric tons, flat YoY (9.19 lakh MT last year) |
| Urea sales | 9.88 lakh metric tons, vs 8.92 lakh MT last year |
| Subsidy receipts | ~₹3,350 cr |
| CPC & SN segment revenue | ₹255 cr, +26% YoY |
| CPC & SN segment contribution | ₹68 cr, +39% YoY |
| Gas cost | $15.85 per MMBTU on NCV basis |
| Net cash | ₹3,000 cr at quarter-end |
| TAN project cumulative expenditure | ₹541 cr as of Jan 25 (₹466 cr as of Dec 31 plus ₹75 cr in Jan) |
| DAP sales volume | ~1 lakh tons |
| Surplus ammonia sales YTD | ~80,000-81,000 tons, with reasonable four-digit profits |
| IMACID Phos Acid expansion investment | $173 million, completion by '27-'28 |
| Q4 urea volume estimate | 1-1.5 lakh tons below normal run rate, due to Gadepan-III turnaround |